Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial-Reference-Cited by-同舟云学术

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

Published:2012-03 Issue:3 Volume:124 Page:563-568
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Randall Leslie M.,Sill Michael W.,Burger Robert A.,Monk Bradley J.,Buening Barbara,Sorosky Joel I.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference26 articles.

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

2. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide;Rustin;J Clin Oncol,2006

3. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels;Rustin;J Clin Oncol,2001

4. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study;Rustin;Ann Oncol,1996

5. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer);Rustin;J Natl Cancer Inst,2004

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei;World Journal of Gastrointestinal Surgery;2023-06-27

2. Outcomes and endpoints of relevance in gynecologic cancer clinical trials;International Journal of Gynecologic Cancer;2023-03

3. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial;Gynecologic Oncology;2021-08

4. The search for surrogacy in patient derived xenograft mouse trials: glass is less than half full;2020-12-03

5. Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer;Molecular and Clinical Oncology;2020-11-12